Could a common heart drug stop diabetes-related heart failure?

NCT ID NCT03744975

Completed Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether the drug Entresto (LCZ 696) can improve how the kidneys and heart handle extra salt and fluid in people with type 2 diabetes. Some participants had early signs of heart stiffness (diastolic dysfunction) and others did not. The goal was to see if the drug could prevent progression to full-blown heart failure. The study involved 72 adults and measured changes in blood and urine markers after a saline infusion.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Entresto (LCZ 696, a neprilysin inhibitor)
What this could lead to: If successful, this could point toward a way to prevent heart failure in people with type 2 diabetes who have early signs of heart stiffness.
What could go wrong: This is a small, early-phase study (72 participants) that measures short-term body responses, not long-term outcomes. The drug may not prevent heart failure in real-world use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2 DIASTOLIC DYSFUNCTION

Contacts and locations

Locations

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.